LYHER HCG series testing products were approved by ANVISA

Recently, Hangzhou Laihe Biotech Co.,Ltd. has made significant progress in the international market. Its HCG series testing products have successfully passed the registration approval of ANVISA in Brazil. This progress not only marks that Laihe Biotech’s products meet the strict standards for entering the Brazilian market, but also lays a solid foundation for the company's further expansion in the South American market.

HCG test kits are widely praised by the market for their fast, simple and reliable detection performance. The products approved by ANVISA in Brazil include HCG test strip (10mIU/ml,25mIU/ml), HCG test midstream (10mIU/ml,25mIU/ml) and HCG test digital midstream (25mIU/ml). These diverse product forms can meet the needs of different markets. In particular, the HCG test digital midstream is equipped with an electronic display that can not only assist early pregnancy detection, but also help determine the pregnant weeks, providing users with great convenience. These products can cover two major application scenarios: home self-testing and professional testing. This flexibility allows products to better serve a wide range of user groups, whether individual users or medical institutions.

In addition, the company is actively promoting the work of obtaining the BGMP certificate and has successfully completed the MDSAP audit. It is expected that Laihe Biotech will obtain the BGMP certificate in 2025, which will further enhance the company's competitiveness in the global market.